RXi Pharma gets exclusive worldwide rights to technology for oral delivery of RNAi therapeutics
Friday, October 17, 2008 17:00 IST Worcester, Massachusetts
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi)